Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Feasibility of Outpatient Yescarta in Large B-cell Lymphoma
NCT05108805Phase 4Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Number of Participants That Received YESCARTA at 6 weeks, Participants That Required Hospitalization at 72 Hours Post Infusion and 3 more. Started Dec 2021; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05108805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108805.